Whole Genome and Exome Sequencing Market to Grow at 13.32% CAGR through 2029F
Advances
in next-generation sequencing technologies and expansion of clinical
applications are expected to drive the Global Whole Genome and Exome Sequencing
Market growth in the forecast period, 2025-2029.
According
to TechSci Research report, “Whole Genome and Exome Sequencing Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2019-2029F”, the Global Whole Genome and Exome Sequencing
Market stood at USD
1.91 Billion in 2023 and is expected to reach USD 4.01 Billion by
2029 with a CAGR of 13.32% during the forecast period.
The
growing awareness of genetic testing among consumers is a significant driver
behind the expansion of the Whole Genome Sequencing (WGS) and Whole Exome
Sequencing (WES) market. Over the past few years, direct-to-consumer (DTC)
genetic testing services, such as 23andMe and MyHeritage, have revolutionized
the accessibility and affordability of genetic testing. These platforms allow
consumers to explore ancestry, health risks, and wellness insights through
simple genetic tests, leading to a surge in consumer interest and awareness of
the potential benefits of genetic information. As these services have become
mainstream, consumers are increasingly seeking comprehensive genetic testing
solutions, including WGS and WES, to gain deeper insights into their health and
well-being.
This
rising awareness is not limited to consumer-focused genetic testing but extends
to the healthcare industry. Patients are increasingly advocating for
personalized healthcare, requesting genetic testing to assess disease risk and
to identify tailored treatment options. This shift in patient behavior is
encouraging healthcare providers to integrate WGS and WES technologies into
routine care, facilitating more precise diagnoses, better treatment outcomes,
and proactive disease management. As patients become more knowledgeable about
the advantages of genetic testing, they are actively seeking out these
services, further driving the demand for advanced genomic sequencing in
clinical settings.
The
impact of consumer awareness is broadening the scope of genomic technologies
beyond traditional research and clinical environments. WGS and WES are no
longer confined to academic laboratories or specialized medical centers but are
gradually becoming mainstream tools in healthcare, offering patients
personalized insights into their genetic makeup. As this consumer-driven shift
continues, the adoption of genomic technologies is expected to grow,
accelerating the market for WGS and WES. With consumers taking a more active
role in their healthcare and seeking out genetic information, the market is
poised for sustained growth as these technologies become increasingly
integrated into everyday healthcare practices.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
"Global Whole Genome and Exome Sequencing Market”
The Global
Whole Genome and Exome Sequencing Market is segmented into product, workflow,
application,
end user, regional distribution, and company
Based
on End-User, The pharmaceutical and biotechnology companies segment is
currently dominating the Global Whole Genome and Exome Sequencing Market. This
dominance is largely driven by the critical role sequencing plays in drug
discovery, development, and personalized medicine. Pharmaceutical and
biotechnology companies are increasingly utilizing Whole Genome Sequencing
(WGS) and Whole Exome Sequencing (WES) to identify genetic mutations associated
with diseases, enabling the development of targeted therapies and novel drugs. Sequencing
is also integral to biomarker discovery, which is crucial for the development
of precision medicine aimed at treating specific genetic profiles. Moreover,
these companies use sequencing technologies in preclinical and clinical studies
to better understand the genetic basis of diseases, predict patient responses
to drugs, and monitor treatment outcomes. The ability to analyze the entire
genome allows for the discovery of new therapeutic targets and enhances the
efficacy of drug development processes. As pharmaceutical and biotechnology
companies continue to invest in research and development (R&D) to bring
innovative treatments to market, the demand for whole genome and exome
sequencing technologies is expected to rise. These companies are also utilizing
sequencing for companion diagnostics, which guide the use of specific drugs for
genetically defined patient groups, further driving their need for sequencing
technologies.
Europe
is the second dominating region in the Global Whole Genome and Exome Sequencing
Market. This dominance can be attributed to the region’s strong healthcare
infrastructure, significant investment in genomic research, and the increasing
adoption of personalized medicine. Countries such as Germany, the United
Kingdom, France, and Switzerland are leading the way in the use of whole genome
and exome sequencing for clinical diagnostics, drug development, and research
applications. In
Europe, the rising prevalence of genetic disorders and an increasing focus on
precision medicine are driving the demand for advanced sequencing technologies.
The European Union has also been instrumental in fostering genomics research
through funding initiatives like the Horizon 2020 program, which supports
large-scale genomic studies and the development of innovative sequencing
methods. The European Society of Human Genetics and similar
organizations are promoting the integration of sequencing technologies into
routine clinical practice. European countries have well-established healthcare
systems and are implementing national policies to support the use of genomic
data for better disease prevention, diagnosis, and treatment. Moreover,
Europe’s regulatory environment is conducive to the growth of the market, with
favorable guidelines for genetic testing and data privacy.
Major
companies operating in Global Whole Genome and Exome Sequencing Market
are:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Novogene Corporation
- Pacific Biosciences of California, Inc.
- QIAGEN N.V.
Download Free Sample Report
Customers
can also request for 10% free customization on this report
“The
development of high-throughput sequencing platforms has greatly reduced the
cost per genome, enabling wider accessibility of sequencing technologies across
various sectors, including research institutions, diagnostic laboratories, and
clinical settings. Newer sequencing methods, such as single-molecule sequencing
and nanopore sequencing, have further enhanced accuracy and read length, making
it possible to capture more comprehensive genomic data in real-time. These
advancements increase the efficiency of both WGS and WES, allowing for the
analysis of entire genomes or specific exonic regions with minimal errors and
better coverage. Improvements in bioinformatics and data analysis
tools have complemented advancements in sequencing technologies.
High-performance computing and artificial intelligence (AI) are now being
employed to process and interpret vast amounts of genomic data, enabling faster
and more reliable results. This enhanced capability makes sequencing an even
more powerful tool for researchers and clinicians. These
technological developments have contributed to the decreasing cost of
sequencing, facilitating its adoption across a range of industries, from
academic research to clinical diagnostics. As technology continues to evolve,
the precision, speed, and affordability of sequencing are expected to drive
even greater market growth, further expanding the use of whole genome and exome
sequencing in both clinical and research applications.,” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Whole Genome
and Exome Sequencing Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, Segmented By Product (Kits, Instruments), By Application (Whole
Genome Sequencing (Oncology, Microbial, Non-Invasive Prenatal Testing (NIPT),
Others), Whole Exome Sequencing (Oncology, Rare Disease, Gene Discovery,
Others)), By End-User (Pharmaceutical and Biotechnology Companies, Diagnostic
Laboratories, Hospitals and Clinics, Research and Academic Institutes, Others),
By Region and Competition, 2019-2029F”, has evaluated the
future growth potential of Global Whole Genome and Exome Sequencing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Whole Genome and Exome Sequencing
Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com